1
|
Lima-Neto RG, Neta MS, Valeriano CA, Neves RP, Lacerda AM, Ferraz CE, Inácio CP, Le Pape P, Ourliac-Garnier I, Faria AR, Silva TG, Pereira VR, Marchand P. Antifungal efficacy of imidazo[1,2- a]pyrazine-based thiosemicarbazones and thiazolidinediones against Sporothrix species. Future Microbiol 2023; 18:1225-1233. [PMID: 37882752 DOI: 10.2217/fmb-2023-0044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2023] [Accepted: 07/06/2023] [Indexed: 10/27/2023] Open
Abstract
Aim: To evaluate antifungal potential of 5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine hybrids based on thiosemicarbazones and thiazolidinediones against pathogenic Sporothrix species. Methods: Antifungal activity of nine compounds were assessed by broth microdilution. Interactions between active compounds and itraconazole were evaluated by the checkerboard assay using non-wild-type isolates. Cytotoxicity of the compounds was determined. Results: Four C-3 substituted analogs showed antifungal activity, unrelated to thiosemicarbazone or thiazolidinedione functions. Synergistic interactions between the four compounds and itraconazole, and low toxicity on mouse fibroblast cells were observed. Activity of 5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine hybrids against Sporothrix depended on the substitution on the imidazopyrazine ring. Conclusion: Antifungal potential, overcoming itraconazole resistance and low toxicity indicate the possible use of that series of compounds in a therapeutic alternative for treatment of sporotrichosis.
Collapse
Affiliation(s)
- Reginaldo G Lima-Neto
- Laboratory for Research & Diagnosis in Tropical Diseases, Department of Tropical Medicine, Center for Medical Sciences, Federal University of Pernambuco (UFPE), Avenida Prof Moraes Rego s/n, Recife, Pernambuco, 50670-901, Brazil
| | - Marlene Sa Neta
- Nantes Université, Cibles et médicaments des infections et de l'immunité, IICiMed, UR 1155, F-44000 Nantes, France
- Department of Pharmaceutical Sciences, Center for Health Sciences, UFPE, Brazil
| | - Carlos At Valeriano
- Laboratory for Research & Diagnosis in Tropical Diseases, Department of Tropical Medicine, Center for Medical Sciences, Federal University of Pernambuco (UFPE), Avenida Prof Moraes Rego s/n, Recife, Pernambuco, 50670-901, Brazil
| | - Rejane P Neves
- Departament of Mycology, Center for Biosciences, UFPE, Brazil
| | | | - Claudia E Ferraz
- Laboratory for Research & Diagnosis in Tropical Diseases, Department of Tropical Medicine, Center for Medical Sciences, Federal University of Pernambuco (UFPE), Avenida Prof Moraes Rego s/n, Recife, Pernambuco, 50670-901, Brazil
| | - Cícero P Inácio
- Departament of Mycology, Center for Biosciences, UFPE, Brazil
| | - Patrice Le Pape
- Nantes Université, Cibles et médicaments des infections et de l'immunité, IICiMed, UR 1155, F-44000 Nantes, France
| | - Isabelle Ourliac-Garnier
- Nantes Université, Cibles et médicaments des infections et de l'immunité, IICiMed, UR 1155, F-44000 Nantes, France
| | - Antônio R Faria
- Department of Pharmaceutical Sciences, Center for Health Sciences, UFPE, Brazil
| | | | - Valéria Ra Pereira
- Aggeu Magalhães Institute, Oswaldo Cruz Fundation, Recife, PE, 50740-465, Brazil
| | - Pascal Marchand
- Nantes Université, Cibles et médicaments des infections et de l'immunité, IICiMed, UR 1155, F-44000 Nantes, France
| |
Collapse
|
2
|
Artunduaga Bonilla JJ, Honorato L, Guimarães AJ, Miranda K, Nimrichter L. Silver Chitosan Nanocomposites are Effective to Combat Sporotrichosis. FRONTIERS IN NANOTECHNOLOGY 2022. [DOI: 10.3389/fnano.2022.857681] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
The use of silver nanoparticles (AgNPs) embedded in polymeric matrix has acquired special attention as a strategy to reduce metal toxicity without losing its antimicrobial effect. In this work, the green synthesis of AgNPs and their functionalization with chitosan (AgNPs@Chi) was performed, and their antifungal activity investigated against the foremost species responsible for causing sporotrichosis, Sporothrix brasiliensis and Sporothrix schenckii. In vitro studies revealed inhibitory concentrations ranging from 0.12–1 μg/ml for both nanocomposites (NCs). Silver release in suspension displayed chitosan as a potential vehicle for continuous silver discharge, with a complete release after 52 days. No synergistic effects were observed in vitro when the NCs were combined with itraconazole or amphotericin B. Treatment of S. brasiliensis with NCs caused morphological deformities, cell membrane discontinuity and an intense cytoplasmic degeneration. Remarkably, both NCs induced the growth and migration of keratinocytes and fibroblasts when compared to control conditions. In addition, functionalization of AgNPs with chitosan significantly reduced its hemolytic activity, suggesting their potential use in vivo. Finally, silver nanocomposites were used as a daily topical treatment in a murine model of subcutaneous sporotrichosis, showing the ability to reduce the Sporothrix infection and stimulate tissue repair. In combination, our results demonstrate that AgNPs@Chi can be a non-toxic and efficient alternative for sporotrichosis.
Collapse
|
3
|
de Souza LCDSV, Alcântara LM, de Macêdo-Sales PA, Reis NF, de Oliveira DS, Machado RLD, Geraldo RB, dos Santos ALS, Ferreira VF, Gonzaga DTG, da Silva FDC, Castro HC, Baptista ARDS. Synthetic Derivatives against Wild-Type and Non-Wild-Type Sporothrix brasiliensis: In Vitro and In Silico Analyses. Pharmaceuticals (Basel) 2022; 15:ph15010055. [PMID: 35056112 PMCID: PMC8781075 DOI: 10.3390/ph15010055] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2021] [Revised: 12/16/2021] [Accepted: 12/21/2021] [Indexed: 02/01/2023] Open
Abstract
Recently, the well-known geographically wide distribution of sporotrichosis in Brazil, combined with the difficulties of effective domestic feline treatment, has emphasized the pressing need for new therapeutic alternatives. This work considers a range of synthetic derivatives as potential antifungals against Sporothrix brasiliensis isolated from cats from the hyperendemic Brazilian region. Six S. brasiliensis isolates from the sporotrichotic lesions of itraconazole responsive or non-responsive domestic cats were studied. The minimum inhibitory concentrations (MICs) of three novel hydrazone derivatives and eleven novel quinone derivatives were determined using the broth microdilution method (M38-A2). In silico tests were also used to predict the pharmacological profile and toxicity parameters of these synthetic derivatives. MICs and MFCs ranged from 1 to >128 µg/mL. The ADMET computational analysis failed to detect toxicity while a good pharmacological predictive profile, with parameters similar to itraconazole, was obtained. Three hydrazone derivatives were particularly promising candidates as antifungal agents against itraconazole-resistant S. brasiliensis from the Brazilian hyperendemic region. Since sporotrichosis is a neglected zoonosis currently spreading in Latin America, particularly in Brazil, the present data can contribute to its future control by alternative antifungal drug design against S. brasiliensis, the most virulent and prevalent species of the hyperendemic context.
Collapse
Affiliation(s)
- Lais Cavalcanti dos Santos Velasco de Souza
- Center for Microorganisms’ Investigation, Fluminense Federal University, Niterói 24020-150, Brazil; (L.C.d.S.V.d.S.); (L.M.A.); (P.A.d.M.-S.); (N.F.R.); (D.S.d.O.); (R.L.D.M.)
| | - Lucas Martins Alcântara
- Center for Microorganisms’ Investigation, Fluminense Federal University, Niterói 24020-150, Brazil; (L.C.d.S.V.d.S.); (L.M.A.); (P.A.d.M.-S.); (N.F.R.); (D.S.d.O.); (R.L.D.M.)
| | - Pãmella Antunes de Macêdo-Sales
- Center for Microorganisms’ Investigation, Fluminense Federal University, Niterói 24020-150, Brazil; (L.C.d.S.V.d.S.); (L.M.A.); (P.A.d.M.-S.); (N.F.R.); (D.S.d.O.); (R.L.D.M.)
| | - Nathália Faria Reis
- Center for Microorganisms’ Investigation, Fluminense Federal University, Niterói 24020-150, Brazil; (L.C.d.S.V.d.S.); (L.M.A.); (P.A.d.M.-S.); (N.F.R.); (D.S.d.O.); (R.L.D.M.)
| | - Débora Sena de Oliveira
- Center for Microorganisms’ Investigation, Fluminense Federal University, Niterói 24020-150, Brazil; (L.C.d.S.V.d.S.); (L.M.A.); (P.A.d.M.-S.); (N.F.R.); (D.S.d.O.); (R.L.D.M.)
| | - Ricardo Luiz Dantas Machado
- Center for Microorganisms’ Investigation, Fluminense Federal University, Niterói 24020-150, Brazil; (L.C.d.S.V.d.S.); (L.M.A.); (P.A.d.M.-S.); (N.F.R.); (D.S.d.O.); (R.L.D.M.)
| | - Reinaldo Barros Geraldo
- Laboratory of Antibiotics, Biochemistry and Molecular Modeling, Institute of Biology, Fluminense Federal University, Niterói 24210-201, Brazil; (R.B.G.); (H.C.C.)
| | - André Luis Souza dos Santos
- Laboratory of Advanced Studies of Emerging and Resistant Microorganisms, Federal University of Rio de Janeiro, Rio de Janeiro 21941-902, Brazil;
| | - Vítor Francisco Ferreira
- Department of Pharmaceutical Technology, Faculty of Pharmacy, Graduate Program in Applied Health Sciences, Niterói 24241-000, Brazil;
- Department of Pharmaceutical Technology, Faculty of Pharmacy, Fluminense Federal University, Niterói 24241-000, Brazil
| | | | | | - Helena Carla Castro
- Laboratory of Antibiotics, Biochemistry and Molecular Modeling, Institute of Biology, Fluminense Federal University, Niterói 24210-201, Brazil; (R.B.G.); (H.C.C.)
| | - Andréa Regina de Souza Baptista
- Center for Microorganisms’ Investigation, Fluminense Federal University, Niterói 24020-150, Brazil; (L.C.d.S.V.d.S.); (L.M.A.); (P.A.d.M.-S.); (N.F.R.); (D.S.d.O.); (R.L.D.M.)
- Correspondence: ; Tel.: +55-21-2629-2559
| |
Collapse
|
4
|
Xue Y, Yin Y, Li H, Chi M, Guo J, Cui G, Li W. Synthesis, Anti-Tumor Activity and Apoptosis-Inducing Effect of Novel Dimeric Keggin-Type Phosphotungstate. Front Pharmacol 2021; 11:632838. [PMID: 33584314 PMCID: PMC7873364 DOI: 10.3389/fphar.2020.632838] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2020] [Accepted: 12/16/2020] [Indexed: 11/22/2022] Open
Abstract
A dimeric Keggin-type phosphotungstate (ODA)10[(PW11FeO39)2O]·9H2O (abbreviated as ODA10[(PW11Fe)2], ODA = octadecyltrimethylammonium bromide) was synthesized and investigated comprehensively its antitumor activity on MCF-7 and A549 cells. The dimeric structure and amorphous morphology were characterized by FT-IR, UV-vis-DRS, SEM and XRD. The in vitro MTT assay of ODA10[(PW11Fe)2] showed anticancer activity on MCF-7 and A549 cells in a dose- and time-dependent manner, and the IC50 values for MCF-7 and A549 cells at 48 h were 5.83 μg/ml and 3.23 μg/ml, respectively. The images of the ODA10[(PW11Fe)2]-treated cells observed by inverted biological microscope exhibited the characteristic morphology of apoptosis. Flow cytometric analysis showed cell apoptosis and cycle arrested at S phase induced by ODA10[(PW11Fe)2]. The above results illuminated the main mechanism of the antitumor action of ODA10[(PW11Fe)2] on MCF-7 and A549 cells, indicating that this dimeric phosphotungstate is a promising anticancer drug.
Collapse
Affiliation(s)
- Yingxue Xue
- School of Pharmacy, Jilin Medical University, Jilin, China
| | - Yifei Yin
- School of Pharmacy, Jilin Medical University, Jilin, China
| | - He Li
- Research and Development Department, NCPC Hebei Lexin Pharmaceutical Co., Ltd., Hebei, China
| | - Mingyu Chi
- School of Pharmacy, Jilin Medical University, Jilin, China
| | - Jiaxin Guo
- School of Pharmacy, Jilin Medical University, Jilin, China
| | - Guihua Cui
- School of Pharmacy, Jilin Medical University, Jilin, China
| | - Wenliang Li
- School of Pharmacy, Jilin Medical University, Jilin, China.,Jilin Collaborative Innovation Center for Antibody Engineering, Jilin Medical University, Jilin, China
| |
Collapse
|